IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Overall, the methylation pattern correlated with the major biological (ZAP-70 and CD38), and molecular (IGHV mutation) markers, distinguishing CLL cases according to IGHV mutational status.
|
24347044 |
2014 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The RPPA investigation and its validation, identified 3 series of proteins: 1) molecules whose expression levels reached statistically significant differences in CLL vs. healthy controls (HSP70, Smac/DIABLO, cleaved PARP, and cleaved caspase-6); 2) proteins with a positive trend of difference in CLL vs. healthy controls (HS1, γ-tubulin, PKC α/β-II Thr-638/641, p38 MAPK Thr-180/Tyr-182, NF-κB Ser-536, Bcl2 Ser-70 and Src Tyr-527); and 3) molecules differentially expressed in patients with IGHV mutations vs. those without mutations (ZAP70, PKC-ζλ, Thr-410/403, and CD45).
|
27312846 |
2016 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
TAp63 mRNA levels were higher in CLL with unmutated IGHV.
|
24117128 |
2013 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that del(13q) conveys an indolent course only in patients with IGHV-mutated CLL.
|
21851216 |
2011 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Most investigated drugs demonstrated similar activity in CLL cells from patients with unmutated and mutated IGHV genes as well as in CLL cells vs. PBMC.
|
19245531 |
2009 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients.
|
31054420 |
2019 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Chromosomal aberrations, IGHV and TP53 mutation status are well-established and essential to discriminate between a more indolent course of disease and a high-risk CLL, which requires an alternative treatment regimen.
|
26890126 |
2016 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
The mutational status of the immunoglobulin heavy chain variable (IGHV) genes identifies two subsets of CLL with different outcomes.
|
23531595 |
2013 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We retrospectively analyzed 463 patients with CLL with available immunoglobulin heavy-chain variable (IGHV) gene status and B-cell receptor (BCR) configuration [heavy-chain complementary-determining region 3 (HCDR3)], of whom thirty-six developed ITP, according to previously defined criteria.
|
22322667 |
2012 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
The reasons for this difference are still unclear, but it has been noted that particular IGHV genes associate with U-CLL vs M-CLL.
|
28125682 |
2017 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Further research of specific IGHV gene usage and subsets of stereotyped BCRs in CLL may be helpful in more precise prediction of CLL prognosis in individual patients.
|
21503826 |
2012 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Mutations in known CLL drivers are seen in only 33% of this cohort, and associated with normal cytogenetics and unmutated IGHV.
|
26638776 |
2015 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
In the present series, 201 (21.9%) of 916 patients with CLL expressed IGHV genes that belonged to 1 of 48 different subsets of sequences with stereotyped heavy chain (H) CDR3.
|
16985177 |
2007 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Samples were split into CLL-Training (n=102) and CLL-Validation (n=114) sets, and an independent supervised analysis for IGHV mutational status was performed considering all genes with gene expression equal or above that of ZAP-70.
|
26038121 |
2015 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The aim of this work was to characterize hTERT splice variants in CLL in relation to disease activity, clinical stage, immunoglobulin heavy chain variable (IGHV) genes mutational status, and TL.
|
23548418 |
2013 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Although the presence of an unmutated IgV(H) gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.
|
15329427 |
2004 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
A marked increase of DEK mRNA expression was observed in the CLL patients with unmutated immunoglobulin heavy chain variable (IGHV) gene (p = 0.025), CD38-positive (p = 0.047), del(17p13) (p = 0.006).
|
23052131 |
2012 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
IgHV1-69 is one of the most frequently rearranged IgHV genes in CLL and the majority of IgHV1-69 cases lack somatic hypermutation and display poor prognosis.
|
18398745 |
2008 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Identical IGHV-D-J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years.
|
20872553 |
2010 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The immunoglobulin heavy chain variable (IGHV) gene mutational status represents a major prognostic marker in chronic lymphocytic leukemia (CLL).
|
23450508 |
2013 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, discordant ISO(+)TNK(-) cases had a IgV(H) gene mutation profile similar to that of concordantly positive cases and different from ZAP-70 concordantly negative B-CLL.
|
16906587 |
2006 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
The existence of subsets that comprise given IGKV-J/IGLV-J domains associated with IGHV-D-J domains that display homologous CDR3 provides further evidence for the role of antigen in CLL pathogenesis.
|
16076869 |
2005 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The expression of several genes correlates closely with the IGHV mutational status and could be used to assess prognosis in CLL.
|
27185377 |
2017 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
It was showed that LPL expression correlates with IgVH mutational status and other clinical or laboratory prognostic factors, and might be applied for the assessment of prognosis in patients with CLL.
|
18616755 |
2009 |
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
We applied high-resolution methylation microarrays (27,578 CpG sites) to assess the global DNA methylation profiles in 20 MCL (10 each with high/low proliferation signature) and 30 CLL (15 poor-prognostic IGHV unmutated subset #1 and 15 good-prognostic IGHV mutated subset #4) samples.
|
22374828 |
2012 |